Jump to section
To democratize access to cutting-edge and personalized care provided by neurologists, mental health providers, and care navigators.
Synapticure is a tele-neurology company providing personalized care for patients and families affected by neurodegenerative diseases. This includes conditions such as Parkinson's, Alzheimer's and related dementia, ALS, and more.
Through its platform, Synapticure's team of neurologists and healthcare professionals are able to remotely diagnose, monitor and treat patients. They provide tailored healthcare plans and ongoing support, aiming to improve quality of life and reduce the burden of in-person visits.
With strong backing, Synapticure is well-equipped to provide this specialized service, and has the potential to make a significant impact on the management of neurodegenerative conditions. Its latest raise will enable the company to broaden partnerships, invest in its technology and expand patient access (among other initiatives.)
Kirsty
Company Specialist at Welcome to the Jungle
Nov 2024
$25m
SERIES A
Feb 2022
$6m
SEED
This company has top investors
Jason Langheier
(Co-Founder & Board Co-Chair)CEO and founder of Foodsmart. Did neuroscience, genetics and bioinformatics research at Williams, Duke, Cambridge and NIH.
Brian Wallach
(Co-Founder & Board Co-Chair)Co-founder of I AM ALS. Previously served as an Assistant United States Attorney in the Northern District of Illinois and as a Senior Vetting Counsel at the White House in the Obama Administration.
Sandra Abrevaya
(CEO & Co-Founder)Former founding CEO of Thrive Chicago. Previously served in senior roles for the City of Chicago, the US House of Representatives, the US Senate, the US Department of Education and the White House.
Data
Operations & Strategy
Finance, Legal & Compliance